… This review will discuss some relevant preclinical models for pharmacology assessment of
… Careful selection of the preclinical model based on the aims of the study can lead to better …

… of preclinical tests required for medicinal products containing genetically modified cells intended
for use in humans, to assess … an overview of key components of the preclinical package. …

… the use of chimeric antigen receptor (CAR) engineered T cells. In this approach, T cells
isolated from patients are engineered to express an activating fusion receptor that binds directly …

… this therapy, but equally crucial are the preclinical models used in testing CAR safety and …
Careful selection of the preclinical model based on the aims of the study (Table 1) can lead …

… In this study, we first evaluated the in vitro function of anti-human CD70 chimeric antigen
receptor (CAR) constructs by fusing different portions of CD27 with CD3-zeta in combination …

… genes of chimeric antigen receptors (CARs) that recognize tumor-associated antigens. We
constructed … We selected the CAR that did not contain the 4-1BB moiety for further preclinical …

… preclinical safety assessment of CART19 was performed on NSG mice, to evaluate the
preclinical … Herein, a comprehensive preclinical safety assessment of CART19 was performed …

… We describe here the preclinical assessment of B7-H3–specific CAR T cells (B7-H3.CAR-T)
as a possible therapy for a subset of patients with AML and our evaluation of the potential …

… with chimeric antigen receptors (CARs) designed to target tumor-specific antigens and
enhance NK cell-mediated anticancer activity. CARs are synthetic receptors that consist of a …

… We systematically compared the preclinical in vitro and in vivo efficacy of T … antigen for
potential immunotherapeutic targeting in patients with AML. Based on this rigorous preclinical …